← All sources View original paper →
Vitamin C for preventing and treating the common cold.
Cochrane review of placebo-controlled trials: regular vitamin C did not meaningfully lower cold incidence in general-community trials (pooled RR 0.97) but showed a large pooled relative reduction in athletes, skiers, and subarctic exercisers (RR 0.48); therapeutic vitamin C at symptom onset did not show consistent benefit on duration or severity.
Design
- Cochrane systematic review; placebo-controlled trials using ≥0.2 g/day vitamin C
- Outcomes: incidence during regular supplementation; duration and severity of episodes; therapeutic trials at onset
Pooled prevention (incidence)
- Community trials (n ≈ 10,708): pooled RR 0.97 (95% CI 0.94–1.00)
- Marathon runners, skiers, soldiers on subarctic exercise (5 trials, n = 598): pooled RR 0.48 (95% CI 0.35–0.64)
Duration / severity themes (regular supplementation)
- Abstract: cold duration reduced ~8% in adults and ~14% in children with regular use; 1–2 g/day shortened colds ~18% in children in reviewed trials
Therapeutic vitamin C (onset of symptoms)
- Seven comparisons (3249 episodes): no consistent effect on duration or severity
Publication
Hemilä H, Chalker E. Cochrane Database Syst Rev. 2013 Jan 31;(1):CD000980. PMID 23440782.
Outcomes
- All-Cause Mortality RiskEvents: /
- All-Cause Mortality RiskEvents: /
- Therapeutic vitamin C started at cold onset: no consistent effect on duration or severity across 7 trial comparisons in the Cochrane abstract.